^
Association details:
| Biomarker: | PIK3CA mutation + HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
Excerpt:
...we performed longitudinal analyses of 97 serial plasma samples collected from 24 patients who were HER2+ to track the resistance during trastuzumab treatment...Patients with PIK3CA/R1/C3 or ERBB2/4 mutations in the baseline plasma had significantly worse progression-free survival....Additionally, mutations in NF1 contributed to trastuzumab resistance...
DOI:
http://dx.doi.org/10.1136/gutjnl-2018-316522
